# Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy

> **NCT07328841** · PHASE3 · RECRUITING · sponsor: **Ming-Yuan Chen** · enrollment: 456 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma (NPC)

## Interventions

- **DRUG:** Full course of PD-1blockades
- **DRUG:** Cisplatin-based induction chemotherapy
- **RADIATION:** Standard-dose radiotherapy
- **RADIATION:** Reduced-dose radiotherapy
- **DRUG:** Concurrent Chemotherapy

## Key facts

- **NCT ID:** NCT07328841
- **Lead sponsor:** Ming-Yuan Chen
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-18
- **Primary completion:** 2030-06-30
- **Final completion:** 2032-06-30
- **Target enrollment:** 456 (ESTIMATED)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07328841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07328841, "Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT07328841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*